Diarrhoea
Diarrhoea is defined as an increased frequency of bowel movements that are loose in consistency. It can be a side effect of Systemic Anti-Cancer Therapy (SACT) and can be debilitating and even life threatening, due to fluid loss and electrolyte imbalance and therefore the impact of severe diarrhoea should not be underestimated.
SACT drugs that are cited as commonly producing diarrhoea are 5-fluorouracil (5-FU), Methotrexate, Irinotecan and Taxanes (Docetaxel, Paclitaxel). However, a wide range of cytotoxic drugs, including monoclonal antibodies and hormonal treatments, and other medicines used in supportive care can also cause diarrhoea. This includes antibiotics and ciclosporin (although it should be noted that almost all drugs will include diarrhoea as a potential side effect). Cancer treatment may also cause diarrhoea indirectly:
SACT-induced diarrhoea may have a dramatic impact on a patient’s quality of life, physical and emotional wellbeing, and invariably increases patient costs. There may be associated abdominal pain, cramping, proctitis, and anal or peri-anal skin breakdown, which in turn can lead to weight loss, malnutrition, sleep disturbance & depression.
This purpose of this guideline is to support medical and nursing staff in managing SACT-induced diarrhoea through advice on:
NB: New agents, monoclonal antibodies or therapies used in Phase I & II clinical trials may have potential side effects and specific monitoring requirements that are not covered in this guideline. Staff should contact the Principle Investigator, Research Nurse or Schiehallion Pharmacists in these cases.
Constipation
Chemotherapy-induced constipation (CIC) is recognised as being a mixture of reduced frequency of bowel action and increased stool consistency; however, the mechanisms of CIC are very poorly defined.
Chemotherapy drugs known to cause constipation are the vinca alkaloids, platinums, thalidomide and hormonal agents, but there is very few published literature on true incidence or mechanism. Potential ways in which chemotherapy can alter the balance of normal gut function and lead to constipation are:
Constipation in patients with cancer is often secondary to drugs that are given to control other chemotherapy, or due to cancer-induced symptoms (such as anti-emetics for nausea and vomiting and opiods for pain) rather than to the chemotherapeutic agents themselves.
Chemotherapy-induced constipation is managed as per the GG&C guidelines (see section 2.2).
2.1 Infection Control Care Plan for Loose Stools (See Appendix 1)
Any member of qualified medical staff can investigate and manage patients with diarrhoea.
4.1 Stool sample pot or universal container
4.2 Patient / carer advice (see Appendix 2)
4.3 Grading Assessment & Adverse Event Tool (see Appendix 3)
4.4 Bowel Movement Record (see Appendix 4)
Patient / carer information is central to the management of SACT-induced diarrhoea, including the possible causes (infection or chemotherapy side effect) and the potential for life threatening dehydration, particularly in babies and young children.
Before starting chemotherapy patients and/or parents should be informed that diarrhoea may occur and what action to take should it do so (see Appendix 2). This should be recorded in the patient casenotes.
Patients / carers will require fluid and nutrition advice in order to maintain satisfactory hydration and nutritional status. A low residue diet with high fluid intake may be appropriate.
If the diarrhoea occurs only after lactose containing foods a secondary lactose intolerance may be the cause and a trial of a lactose free diet may be appropriate. Where this is suspected it should be discussed with the dietitian.
Patients / carers must be informed that children with poor fluid intake and diarrhoea must be presented to the Schiehallion Daycare Ward or their local shared care hospital for assessment.
Accurate pre-chemotherapy assessment is essential to enable variation from the patient’s baseline to be detected. The following should be recorded for all patients:
After obtaining a detailed history from the patient, the doctor should inspect the bowel movements if possible, or speak to a nurse who has done so.
The following should be noted in the casenotes:
To confirm whether the diarrhoea is related to SACT or infection, fresh stool specimens should be sent to the Microbiology Laboratory testing and should include:
Stool specimens should also be sent to Virology, WoSSVC, GRI
In acute onset diarrhoea with liquid stools, Norovirus or Astrovirus should be suspected and screened weekly by Faeces Viral PCR screen (includes Norovirus, Astrovirus Rotavirus, Adenovirus and Sapovirus) and Cryptosporidium PCR (send to Parasitology Reference Laboratory, SPDRL, GRI). Other pathogens such as Giardia should be considered and appropriate samples sent for investigation.
All patients with microbiological pathogens in their stool should be isolated until they have been shown to be negative on at least 2 consecutive specimens. For viral pathogens repeat testing is not helpful and patients should be isolated until symptoms have resolved.
In patients in whom no infective agent has been isolated from initial culture and an infective cause of diarrhoea remains likely, 3 stool samples taken on consecutive days should be submitted. Further sampling after that point is unlikely to yield additional results and should not be performed. If necessary, please discuss this with the Consultant.
Patients should be investigated by a rectal biopsy (plus or minus an upper GI endoscopic biopsy) which can be organised through the gastroenterology service. Tissue specimens for virology should be sent in virus transport medium for EBV, CMV, Adenovirus PCR, Gastroenteritis PCR and Enterovirus PCR testing to WoSSVC, GRI.
Medical and nursing management of all patients with SACT-induced diarrhoea should:
Where relevant see the patient’s specific clinical trial protocol or national treatment guideline for grading criteria or use Appendix 3 where there is no relevant protocol/guideline.
Whilst your child is at home on chemotherapy or post-radiotherapy it is important that you monitor their health. Most importantly are fever (make contact urgently if temperature is above 38o) and bowel movements.
Please call the Schiehallion Daycare Ward (2B) on 0141 452 4476 / 4476 during the hours of 08:30 to 19:00 (Monday to Friday) or the Schiehallion Ward (2A) on 0141 452 4450 / 4451 outside of these hours/days for advice if your child develops diarrhoea at home.
If they present with any of the following, please call immediately:
It is important to rule out infection when a patient develops diarrhoea and therefore advice should always be sought before commencing any anti-diarrhoeal medication. If infection is ruled out the following guidance will be recommended:
Diarrhoea Grading Assessment:
GRADE |
CRITERIA |
MANAGEMENT |
1 |
2 – 3 stools per day |
Commence loperamide (Imodium):
|
2 |
4 – 6 stools per day or moderate cramps |
As Grade 1:
|
3 |
7 – 9 stools per day or severe cramps |
Withhold chemotherapy:
|
4 |
>10 stools per day, bloody, parenteral support required |
Urgent medical review:
|
Common Terminology Criteria for Adverse Events:
TOXICITY |
GRADE 1 |
GRADE 2 |
GRADE 3 |
GRADE 4 |
GRADE 5 |
Diarrhoea (without stoma) |
Increase of <4 stools per day |
Increase of <4 – 6 stools |
Increase of >7 stools per |
Requires intensive |
Death |
Diarrhoea (with stoma) |
Mild increase in loose watery output |
Moderate increase in loose watery output (>3 – 4) |
Severe increase in output, interfering with normal |
Requires intensive |
Death |
Last reviewed: 01 May 2021
Next review: 31 May 2023
Author(s): Dr Milind Ronghe
Version: 3
Approved By: Schiehallion Unit Clinical Governance Group